AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23943468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent, CD4-guided antiretroviral therapy (ART)
Number of subjects: 258
Study 23943468 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy (ART)
Number of subjects: 258
Study 23943468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 258
Study 21707134 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 112
Study 21707134 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (Placebo)
Number of subjects: 112
Study 18313033 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 150
Study 18313033 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Coping Enhancement Training (CCET)
Number of subjects: 150
Study 18313033 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 150
Study 16496019 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric Resistance Training (CRT)
Number of subjects: 29
Study 16496019 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Resistance Training (ERT)
Number of subjects: 29
Study 16496019 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 29
Study 14739727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 14739727 — intervention group
Group type: COMPARATOR
Intervention: Sotalol or Propafenone
Number of subjects: 0
Study 14739727 — intervention group
Group type: COMPARATOR
Intervention: Recurrent Atrial Fibrillation
Number of subjects: 0
Study 10626595 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 consecutive nights of exposure to power-frequency magnetic fields at occupational intensity (28.3 microtesla)
Number of subjects: 30
Study 10626595 — intervention group
Group type: COMPARATOR
Intervention: Equivalent no-exposure sham control conditions
Number of subjects: 30
Study 9105355 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous posterior pharyngeal wall augmentation using a rolled superiorly based pharyngeal myomucosal flap
Number of subjects: 14
Study 9105355 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous posterior pharyngeal wall augmentation
Number of subjects: 14
Study 8231271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation with a 30‐ or 35‐mm balloon dilator, one or two balloon inflations, and 20, 40, or 60 seconds per balloon inflation
Number of subjects: 14
Study 8231271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 14
Study 3991280 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 2 mg/kg orally at diagnosis followed by 1 mg/kg 12 hours later if symptoms persisted
Number of subjects: 50
Study 3991280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 50
Study 31362877 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4+ with poor metabolic phenotype
Number of subjects: 497
Study 31362877 — intervention group
Group type: COMPARATOR
Intervention: ApoE4- healthy phenotype
Number of subjects: 497
Study 31362877 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4+ poor metabolic phenotype
Number of subjects: 497
Study 31362877 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE4+ women
Number of subjects: 497
Study 31362877 — intervention group
Group type: COMPARATOR
Intervention: ApoE4- women
Number of subjects: 497
Study 28558139 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant solution
Number of subjects: 33
Study 28558139 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 33
Study 26055735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1601
Study 26055735 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 1601
Study 24267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with levothyroxine (n=45; 61.6%)
Number of subjects: 258
Study 24267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated women with AITD and/or subclinical hypothyroidism (n=38; 14.7%)
Number of subjects: 258
Study 24267864 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid women without signs of AITD (Control group, n=147; 57.0%)
Number of subjects: 258
Study 24267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with levothyroxine
Number of subjects: 258
Study 24267864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 258
Study 21878104 — intervention group
Group type: EXPERIMENTAL
Intervention: DAFNE program
Number of subjects: 40
Study 19726314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin enteric capsules (200 mg)
Number of subjects: 9
Study 19726314 — intervention group
Group type: COMPARATOR
Intervention: Tiopronin tablets (200 mg)
Number of subjects: 9
Study 17416857 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (wD)
Number of subjects: 865
Study 17416857 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel once every 3 weeks (3wD)
Number of subjects: 865
Study 15108296 — intervention group
Group type: EXPERIMENTAL
Intervention: [H2O]-PET
Number of subjects: 0
Study 15108296 — intervention group
Group type: EXPERIMENTAL
Intervention: LORETA
Number of subjects: 0
Study 15108296 — intervention group
Group type: COMPARATOR
Intervention: Statistical analysis
Number of subjects: 0
Study 11877068 — intervention group
Group type: EXPERIMENTAL
Intervention: SIIST with HGFs
Number of subjects: 73
Study 11877068 — intervention group
Group type: COMPARATOR
Intervention: SIIST alone
Number of subjects: 73
Study 9626635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risedronate, 30 mg/day for 84 days
Number of subjects: 162
Study 9626635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risedronate, 30 mg/day for 84 days (repeated administration)
Number of subjects: 162
Study 7882703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen (1600 mg taken in the evening)
Number of subjects: 24
Study 7882703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (substituted for a single dose of active treatment)
Number of subjects: 24
Study 2979246 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg o.m.
Number of subjects: 7
Study 2979246 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 7
Study 31621186 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system
Number of subjects: 38
Study 29669442 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME)
Number of subjects: 32
Study 28095101 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi‐NRT with VF
Number of subjects: 20
Study 28095101 — intervention group
Group type: COMPARATOR
Intervention: Axi‐NRT without VF
Number of subjects: 20
Study 24872078 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT-BIG
Number of subjects: 42
Study 24872078 — intervention group
Group type: COMPARATOR
Intervention: AOT-SP
Number of subjects: 42
Study 23577799 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (543 mg/day in BeneFlax)
Number of subjects: 94
Study 23577799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 21323532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular phone reminder system (ARemind) - personalized text messages daily
Number of subjects: 23
Study 21323532 — intervention group
Group type: COMPARATOR
Intervention: Beeper (BP) - reminder beep at the time of dosing
Number of subjects: 23
Study 19175889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 microg once daily (QD)
Number of subjects: 112
Study 19175889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 17445806 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 80
Study 17445806 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU hCG
Number of subjects: 80
Study 17445806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500 IU hCG
Number of subjects: 80
Study 14997197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT orally each day for 2 years
Number of subjects: 205
Study 14997197 — intervention group
Group type: COMPARATOR
Intervention: 300 mg UFT alone orally each day for 2 years
Number of subjects: 205
Study 14997197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT in stage III patients
Number of subjects: 205
Study 14997197 — intervention group
Group type: COMPARATOR
Intervention: 300 mg UFT alone in stage III patients
Number of subjects: 205
Study 14997197 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT
Number of subjects: 205
Study 14551553 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12578082 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining a constant preload
Number of subjects: 14
Study 12578082 — intervention group
Group type: COMPARATOR
Intervention: Maintaining a constant degree of thumb abduction
Number of subjects: 14
Study 12578082 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected preload
Number of subjects: 14
Study 7780046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 5 mg
Number of subjects: 16
Study 7780046 — intervention group
Group type: COMPARATOR
Intervention: Stavudine 10 mg
Number of subjects: 16
Study 7780046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg
Number of subjects: 16
Study 7780046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg
Number of subjects: 16
Study 2083186 — intervention group
Group type: EXPERIMENTAL
Intervention: iproplatin (240 mg/m2)
Number of subjects: 88
Study 2083186 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (100 mg/m2)
Number of subjects: 88
Study 2083186 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin (300 mg/m2)
Number of subjects: 88
Study 40440 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/day of lecithin
Number of subjects: 6
Study 40440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31526123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1382
Study 31526123 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1382
Study 31526123 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex AAA
Number of subjects: 1382
Study 31526123 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncomplex AAA
Number of subjects: 1382
Study 31526123 — intervention group
Group type: EXPERIMENTAL
Intervention: No AAA
Number of subjects: 1382
Study 28260458 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/d valganciclovir
Number of subjects: 201
Study 28260458 — intervention group
Group type: COMPARATOR
Intervention: 900 mg/d valganciclovir
Number of subjects: 201
Study 27071541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 8229
Study 24727123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin for 12 weeks then response-guided therapy with peginterferon α‐2a/ribavirin for 12 or 36 weeks
Number of subjects: 183
Study 24727123 — intervention group
Group type: COMPARATOR
Intervention: Placebo with peginterferon α‐2a/ribavirin for 12 weeks then peginterferon α‐2a/ribavirin for 36 weeks
Number of subjects: 183
Study 24727123 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin
Number of subjects: 183
Study 24727123 — intervention group
Group type: COMPARATOR
Intervention: Placebo with peginterferon α‐2a/ribavirin
Number of subjects: 183
Study 22311997 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated ostracism (ostracized condition)
Number of subjects: 19
Study 22311997 — intervention group
Group type: COMPARATOR
Intervention: Inclusion/control condition
Number of subjects: 19
Study 18626666 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-focused psychosocial intervention
Number of subjects: 54
Study 18626666 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 18251154 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple‐plus‐probiotics group (1 week of PPI-based triple therapy + 8 weeks of probiotics)
Number of subjects: 352
Study 18251154 — intervention group
Group type: COMPARATOR
Intervention: Triple‐only group (1 week of PPI-based triple therapy without probiotics)
Number of subjects: 352
Study 16340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) targeting either the globus pallidum internus (GPi) or subthalamic nucleus (STN)
Number of subjects: 0
Study 16340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS)
Number of subjects: 0
Study 16340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training using external visual or auditory cues
Number of subjects: 0
Study 16340102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of deep brain stimulation, pharmacotherapy, and rehabilitation training
Number of subjects: 0
Study 12474117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 12474117 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 12474117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol in frequent low doses (0.075 mg/kg every 30 minutes)
Number of subjects: 298
Study 9787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ipratropium bromide (250 micrograms)
Number of subjects: 298
Study 9787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol in frequent low doses
Number of subjects: 298
Study 9787684 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol in hourly high doses (0.15 mg/kg every 60 minutes)
Number of subjects: 298
Study 7625415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual estradiol‐17 beta (1 mg)
Number of subjects: 11
Study 7625415 — intervention group
Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 11
Study 31930464 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk identification tool for repeated intimate partner violence
Number of subjects: 238
Study 31930464 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrator characteristics (unemployment, lack of regret, other violent criminal history, history of being beaten by a family member)
Number of subjects: 238
Study 31930464 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim characteristics (nonqualified education, predictions of future harm)
Number of subjects: 238
Study 31930464 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship characteristics (different ethnicity, poor socioeconomic status, difference in incomes, living in a rental property, alcohol and drug use, unprocessed previous history of physical violence)
Number of subjects: 238
Study 29898452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention including regular monitoring and follow-up
Number of subjects: 865
Study 26838934 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction with hamstring tendon graft (DB‐HT)
Number of subjects: 150
Study 26838934 — intervention group
Group type: COMPARATOR
Intervention: Rectangular-tunnel single-bundle ACL reconstruction with patellar tendon graft (RTSB‐PT)
Number of subjects: 150
Study 26838934 — intervention group
Group type: COMPARATOR
Intervention: RTSB‐PT
Number of subjects: 150
Study 26838934 — intervention group
Group type: EXPERIMENTAL
Intervention: DB‐HT
Number of subjects: 150
Study 26838934 — intervention group
Group type: EXPERIMENTAL
Intervention: DB‐HT and RTSB‐PT
Number of subjects: 150
Study 25404126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment (IST) with artemether-lumefantrine (AL)
Number of subjects: 30
Study 25404126 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Preventive Treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Number of subjects: 30
Study 23563134 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 23563134 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 21070457 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐mg/mL cohesive gel alone
Number of subjects: 90
Study 21070457 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA alone
Number of subjects: 90
Study 21070457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 24‐mg/mL cohesive gel and onabotulinumtoxinA
Number of subjects: 90
Study 21070457 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 18271883 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 400
Study 16564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg daily)
Number of subjects: 40
Study 16564798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16564798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 40
Study 12548091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoprostenol
Number of subjects: 0
Study 12548091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treprostinil
Number of subjects: 0
Study 12548091 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil
Number of subjects: 0
Study 12548091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11007152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-deception scores in Study 1
Number of subjects: 220
Study 11007152 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-deception scores in Study 2
Number of subjects: 220
Study 9360182 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents + 4 mg PGE2 gel
Number of subjects: 44
Study 9360182 — intervention group
Group type: COMPARATOR
Intervention: PGE2 gel alone
Number of subjects: 44
Study 1548570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (100 mg p.o. daily)
Number of subjects: 86
Study 1548570 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg p.o. daily)
Number of subjects: 86
Study 4033132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.23 g/kg alcohol
Number of subjects: 11
Study 4033132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.46 g/kg alcohol
Number of subjects: 11
Study 4033132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 4033132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 g/kg alcohol
Number of subjects: 11
Study 30021578 — intervention group
Group type: EXPERIMENTAL
Intervention: PrevOP-PAP intervention (PrevOP-PAP-I)
Number of subjects: 240
Study 30021578 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (PrevOP-PAP-CTRL)
Number of subjects: 240
Study 29228919 — intervention group
Group type: EXPERIMENTAL
Intervention: CARe methodology training
Number of subjects: 263
Study 29228919 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 263
Study 26270552 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality modulation of self-agency (SA)
Number of subjects: 16
Study 23963138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 479
Study 23963138 — intervention group
Group type: COMPARATOR
Intervention: Non-resected LLD patients
Number of subjects: 479
Study 23963138 — intervention group
Group type: COMPARATOR
Intervention: Non-resected non-LLD patients
Number of subjects: 479
Study 21406135 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 0
Study 21406135 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT
Number of subjects: 0
Study 18164094 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0.15 U/kg)
Number of subjects: 18
Study 18164094 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro (0.15 U/kg)
Number of subjects: 18
Study 17006711 — intervention group
Group type: EXPERIMENTAL
Intervention: 40%T (exercise at 40% of VO(2)max)
Number of subjects: 10
Study 17006711 — intervention group
Group type: EXPERIMENTAL
Intervention: 60%T (exercise at 60% of VO(2)max)
Number of subjects: 10
Study 17006711 — intervention group
Group type: EXPERIMENTAL
Intervention: 70%T (exercise at 70% of VO(2)max)
Number of subjects: 10
Study 17006711 — intervention group
Group type: COMPARATOR
Intervention: Ctr (control trial, no exercise)
Number of subjects: 10
Study 12892384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-orotate (3000 mg/day for 90 days)
Number of subjects: 20
Study 12892384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10756246 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of contrast agent at different rates (3 rates, 10 or 20 minutes duration).
Number of subjects: 19
Study 10756246 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of contrast agent.
Number of subjects: 19
Study 10756246 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic triggered imaging with MI of 1.5.
Number of subjects: 19
Study 10756246 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic triggered imaging.
Number of subjects: 19
Study 8650428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil ethyl ester (Esapent, 5.1 g/day)
Number of subjects: 14
Study 8650428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1501052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IgM enriched immunoglobulin
Number of subjects: 18
Study 1501052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 6593146 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% neutral solution of sodium fluoride, 10 ml, rinsed every second week during the school year
Number of subjects: 365
Study 6593146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 29575737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intraarticular glucocorticoid injections
Number of subjects: 0